US · FLGT
Fulgent Genetics, Inc.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- El Monte, CA 91780
- Website
- fulgentgenetics.com
Price · as of 2025-12-31
$14.13
Market cap 473.89M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $293.35 | +1,976.08% |
| Intrinsic Value(DCF) | $8.27 | -41.47% |
| Graham-Dodd Method(GD) | $25.49 | +80.36% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | $0.00 | $0.00 | |||
| 2016 | $11.05 | $519.94 | $8,249.38 | $0.00 | $0.00 |
| 2017 | $3.85 | $65.65 | $104.45 | $2.34 | $0.00 |
| 2018 | $5.18 | $126.39 | $8.69 | $1.35 | $0.00 |
| 2019 | $16.70 | $746.00 | $112.48 | $4.32 | $0.00 |
| 2020 | $95.60 | $2,345.18 | $13,109.35 | $72.31 | $10,883.72 |
| 2021 | $54.20 | $195.61 | $852.85 | $123.94 | $2,374.71 |
| 2022 | $30.55 | $121.46 | $1.32 | $61.16 | $0.00 |
| 2023 | $22.91 | $47.51 | $4.11 | $9.23 | $240.92 |
| 2024 | $18.59 | $34.55 | $10.72 | $29.69 | $0.00 |
| 2025 | $14.20 | $293.35 | $6.37 | $25.48 | $0.00 |
AI valuation
Our deep-learning model estimates Fulgent Genetics, Inc.'s (FLGT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $293.35
- Current price
- $14.13
- AI upside
- +1,976.08%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$8.27
-41.47% upside
Graham-Dodd
$25.49
+80.36% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| FLGT | Fulgent Genetics, Inc. | $14.13 | 473.89M | +1,976% | -41% | +80% | — | -7.09 | 0.39 | 1.35 | -2.21 | -17.85 | 0.43 | 40.56% | -19.10% | -18.75% | -5.49% | -6.54% | -5.07% | 0.00 | -821.75 | 6.48 | 4.95 | 1.08 | 3972.00% | 1383.00% | 54509.00% | -28.42% | -1.20 | -14.97% | 0.00% | 0.00% | 3.19% | -1.65 | -0.82 | 0.31 | 3.63 |
| ARVN | Arvinas, Inc. | $13.27 | 974.25M | +82% | -40% | -97% | — | -10.76 | 2.00 | 3.31 | -2.55 | — | 2.00 | 98.02% | -43.75% | -30.77% | -16.23% | 32.32% | -8.93% | 0.02 | — | 4.92 | 4.88 | 1.78 | -5379.00% | -30.00% | 559.00% | -31.73% | -1.92 | 77.55% | 0.00% | 0.00% | 15.59% | -1.67 | -0.70 | 0.73 | -0.54 |
| AVXL | Anavex Life Sciences Corp… | $4.43 | 410.54M | — | — | — | — | -8.09 | 3.96 | — | -5.88 | -210.39 | 3.96 | 0.00% | — | — | -43.11% | 523.72% | -38.75% | 0.00 | — | 11.60 | 11.56 | 2.21 | 385.00% | — | 2672.00% | -10.40% | -4.36 | 397.76% | 0.00% | 0.00% | 0.00% | -5.30 | -6.98 | — | 19.47 |
| BFLY | Butterfly Network, Inc. | $3.79 | 957.36M | +668% | -29% | — | — | -12.35 | 4.85 | 9.75 | -12.15 | — | 5.05 | 46.85% | -88.53% | -78.95% | -42.25% | -104.05% | -27.89% | 0.09 | -58.00 | 3.83 | 2.72 | 1.97 | -882.00% | 1896.00% | -6386.00% | -1.69% | -0.20 | -19.32% | 0.00% | 0.00% | 7.02% | -9.47 | -51.01 | 8.39 | 1.64 |
| CDNA | CareDx, Inc | $18.76 | 964.88M | +90% | -24% | -84% | — | -46.78 | 3.30 | 2.63 | -1261.39 | — | 4.33 | 66.99% | -5.53% | -5.62% | -6.27% | -14.41% | -4.72% | 0.06 | — | 2.86 | 2.45 | 68.59 | -14301.00% | 1379.00% | 1443.00% | 3.62% | 0.47 | 24.76% | 0.00% | 0.00% | 8.79% | -40.03 | 23.29 | 2.22 | 4.19 |
| CSTL | Castle Biosciences, Inc. | $29.57 | 863.11M | +72% | -30% | -71% | — | -33.58 | 1.72 | 2.36 | 48.38 | — | 2.19 | 68.66% | -12.44% | -7.02% | -5.21% | -17.64% | -4.35% | 0.08 | -497.79 | 5.26 | 4.99 | -7.04 | -23387.00% | 366.00% | -2248.00% | 3.49% | 0.94 | 14.26% | 0.00% | 0.00% | 0.00% | -12.82 | 19.37 | 1.59 | 4.94 |
| DRIO | DarioHealth Corp. | $11.97 | 80.9M | +162% | -51% | — | — | -22.91 | 13.60 | 36.23 | -19.50 | — | -234.90 | 49.06% | -213.55% | -158.09% | -65.68% | -88.81% | -39.71% | 0.42 | -601.50 | 2.44 | 2.03 | -0.05 | -6839.00% | 3286.00% | 2499.00% | -3.95% | -2.32 | -62.10% | 0.00% | 0.00% | 0.00% | -16.99 | -25.36 | 36.29 | 6.81 |
| MYGN | Myriad Genetics, Inc. | $4.61 | 429.72M | +702% | -57% | — | — | — | 1.27 | 0.57 | -1.33 | — | 2.87 | 69.93% | -16.90% | -44.38% | 0.00% | -22.11% | 0.00% | 0.57 | -11.51 | 2.49 | 1.98 | -0.15 | 18085.00% | -156.00% | -10469.00% | 0.39% | 0.01 | 0.31% | 0.00% | — | 0.00% | -3.79 | 293.13 | 0.64 | -0.54 |
| PACB | Pacific Biosciences of Ca… | $1.68 | 507.2M | +1,311% | -61% | — | — | -0.89 | 90.85 | 3.04 | -28.24 | -1.27 | -1.48 | 31.67% | -348.46% | -341.47% | -213.45% | -87.50% | -53.45% | 141.98 | -80.18 | 6.89 | 5.79 | -14.03 | 7009.00% | 389.00% | -4633.00% | -23.44% | -2.04 | -17.88% | 0.00% | 0.00% | 28.22% | -1.73 | -8.48 | 6.04 | -1.28 |
| PSNL | Personalis, Inc. | $9.06 | 804.57M | +263% | — | — | — | -9.95 | 3.10 | — | -8.46 | — | 3.10 | 0.00% | — | — | -35.02% | -152.75% | -26.89% | 0.12 | -429.55 | 6.76 | 6.46 | 1.30 | -3358.00% | -10000.00% | 6994.00% | -9.83% | -1.89 | -137.82% | 0.00% | 0.00% | 5.59% | -6.82 | -7.56 | — | 3.95 |
| VALN | Valneva SE | $11.09 | 954.23M | +215% | -66% | -82% | — | -34.66 | 2.34 | 2.50 | 14.73 | — | 2.72 | 41.89% | 7.86% | -7.22% | -7.91% | 6.06% | -2.55% | 1.19 | 0.56 | 2.61 | 1.78 | 1.50 | -8836.00% | 1032.00% | -6146.00% | -19.71% | -0.59 | -38.00% | 0.00% | 0.00% | 8.17% | 35.45 | -5.65 | 2.79 | 0.09 |
About Fulgent Genetics, Inc.
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
- CEO
- Ming Hsieh
- Employees
- 1.31K
- Beta
- 0.94
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($8.27 ÷ $14.13) − 1 = -41.47% (DCF, example).